Last updated on April 18, 2014 at 0:09 EDT

Occlutech CEO Wins Patent Lawsuit by St Jude-AGA Medical

September 26, 2011

JENA, Germany, September 26, 2011 /PRNewswire/ –

Occlutech, a leading European developer of implants for treating
structural heart disease today announced that its CEO, Mr Tor Peters, has
obtained a favorable ruling from the district court in Duesseldorf in patent
litigation initiated personally against him by St Jude AGA Medical.

On the 10th of May 2011, Occlutech GmbH won an over 5 years long patent
lawsuit initiated by St Jude-AGA Medical at the German Supreme Court in
Karlsruhe regarding infringement of patent EP 808 138.

In further proceedings at the Regional Court in Duesseldorf, St Jude-AGA
Medical accused the CEO of Occlutech GmbH, Mr Tor Peters, privately for
alleged violation of patent EP 808 138. In a ruling dated September 8th
2011, this claim has now also been rejected by the District Court in
Duesseldorf. The ruling is subject to appeal by St Jude-AGA Medical.

Tor Peters says; “It is amazing and quite shocking to see a company that
you would normally consider ethical, going to such length in trying to kill
a competitor by also going after private individuals with this kind of
massive and unjustified litigation. Obviously we are very happy that the
courts in Germany now ruled in our favor as courts in The UK, The
Netherlands and Sweden have done before.”

Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities such as Atrial Septal Defects,
(ASD), and Patent Foramen Ovale (PFO, an undesired channel between the
heart’s two atria, present in up to 25% of the population), in minimally
invasive, non-surgical procedures. The market for PFO occluders is expected
to expand significantly as the link between PFO and stroke, that is the
third most common cause of death, as well as severe migraine becomes
increasingly well documented.

SOURCE Occlutech GmbH

Source: PR Newswire